

IZAZOVI U RAZVOJU BIOTEHNOLOŠKIH LEKOVA – PERSPEKTIVA PROIZVOĐAČA LEKOVA

Bojan Trkulja*

Udruženje Inovia, Beograd, Srbija

*bojan.trkulja@inovia.rs

Zahvaljujući inovativnim lekovima pacijenti danas žive duže i kvalitetnije, zdravstveni sistemi beleže uštede u delu budžeta koji se ne odnosi na lekove, a zajednica ima korist od pacijenata čija je bolest dovoljno dobro kontrolisana da ostaju produktivni članovi društva. Broj novoregistrovanih inovativnih lekova raste iz godine u godinu, ali je opet nedovoljan da pokrije sve oblasti u kojima i dalje imamo nepovoljne ishode lečenja. Razlozi za to su višestruki. Sa jedne strane, proces razvoja jednog inovativnog leka traje veoma dugo, dok sa druge strane troškovi razvoja takve terapije sve više rastu. Međutim, glavni uzrok zbog kojeg nemamo više inovativnih terapija je ogromna neizvesnost koja prati razvoj jednog takvog leka. Šta su najveći izazovi u razvoju ovih terapija na strani inovativnih farmaceutskih kompanija, kako se efikasnije mogu otkloniti administrativne prepreke u razvoju novih lekova i da li postoji način da ove terapije budu dostupnije neka su od pitanja kojima se bavi ovo predavanje.

<https://doi.org/10.5937/arhfarm-61879>

**CHALLENGES IN THE DEVELOPMENT OF BIOTECHNOLOGICAL DRUGS -
THE PERSPECTIVE OF DRUG MANUFACTURERS**

Bojan Trkulja*

Inovia Association, Belgrade, Serbia

*bojan.trkulja@inovia.rs

Thanks to innovative medicines, patients are now living longer and better lives, health systems are saving on the non-drug part of the budget, and the community benefits from patients whose disease is controlled enough to remain productive members of society. The number of newly registered innovative drugs is growing year by year, but it is not enough to cover all areas in which we still have unfavorable treatment outcomes. The reasons for this are multiple. On the one hand, the process of developing an innovative drug takes a very long time, while on the other hand, the costs of developing such therapy are increasing. However, the main reason why we do not have more innovative therapies is the enormous uncertainty that accompanies the development of such a drug. What are the biggest challenges in the development of these therapies on the part of innovative pharmaceutical companies, how can administrative obstacles in the development of new drugs be removed more efficiently and is there a way to make these therapies more accessible are some of the questions addressed in this lecture.